Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has reported second-quarter 2026 net product revenue of approximately $13.5 million, a significant increase from $2 million in the same period last year. This growth was primarily driven by approximately $11 million in net sales of TONMYA, the company's recently approved treatment for fibromyalgia. The drug recorded 12,592 total prescriptions during the quarter, up 100% sequentially, with new patient prescriptions increasing 36% and refills rising 207%.
TONMYA's market penetration is expanding rapidly, with coverage now representing approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. This coverage is expected to increase to approximately 145 million lives when a managed Medicare agreement takes effect on January 1, 2027. The strong prescription growth and expanding coverage indicate that TONMYA is gaining traction among healthcare providers and patients, addressing a significant unmet need in fibromyalgia treatment.
Beyond TONMYA's commercial success, Tonix continues to advance its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder. Additionally, Tonix is preparing to begin an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. These developments highlight Tonix's commitment to expanding its portfolio in central nervous system (CNS) and immunology treatments.
The company ended the quarter with approximately $176.2 million in cash and cash equivalents. Management stated that these resources, together with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second quarter 2027. This financial stability provides a solid foundation for ongoing research and development efforts.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on CNS and immunology treatments in areas of high unmet medical need. TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg) is the first new treatment for fibromyalgia in more than 15 years. The company's CNS commercial infrastructure also supports its acute migraine products, Zembrace SymTouch and Tosymra. Tonix is exploring TONMYA's potential in Phase 2 clinical trials for major depressive disorder and acute stress disorder. The pipeline also includes TNX-2900 for Prader-Willi syndrome and immunology programs such as TNX-4800 for Lyme disease prophylaxis and TNX-1500 for kidney transplant rejection prevention.
The robust sales performance and pipeline progress underscore Tonix's strategic focus on addressing high unmet medical needs. For leaders in the biotechnology and pharmaceutical sectors, this growth signals the potential for innovative treatments to achieve commercial success while expanding therapeutic applications. The company's financial position and operational advancements position it well for future milestones, including the managed Medicare coverage expansion and ongoing clinical trials.
For more information, visit the company's newsroom at https://nnw.fm/TNXP and the full press release at https://nnw.fm/6Yytj.
